Progressive Loss of Sensitivity to Growth Control by Retinoic Acid and Transforming Growth Factor-Beta at Late Stages of Human Papillomavirus Type 16-Initiated Transformation of Human Keratinocytes

  • Kim E. Creek
  • Gemma Geslani
  • Ayse Batova
  • Lucia Pirisi
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 354)

Abstract

Human papillomavirus (HPV), especially HPV types 16, 18, and 33, play an important role in the development of cervical cancer.1–3 We,4,5 as well as others,6–9 have shown that DNA from these HPV types immortalize cultured human foreskin keratinocytes (HKc) and human cervical cells. HPV 16-immortalized HKc (HKc/HPV16) represent an attractive in vitro model system to study the process of multistep carcinogenesis in human cells, and for identifying agents that can modify or prevent HPV-induced transformation, since they undergo malignant conversion through four phenotypically defined “steps” or stages. Although immortal, HKc/HPV 16 are not tumorigenic and retain many features characteristic of normal HKc, including a requirement for epidermal growth factor (EGF) and bovine pituitary extract (BPE) for proliferation.4,5 In the next step of this progression model, growth factor independent sublines, HKc/GFI, that no longer require EGF and BPE for proliferation, are selected from HKc/HPV16.5,10 Next, sublines that no longer respond to calcium and serum-induced differentiation, HKc/DR, are selected from HKc/GFI.5 In the final step, malignant conversion of HKc/DR is achieved by transfection with viral Harvey ras (v-Ha-ras) or herpes simplex virus type 2 DNA.11,12 The steps from immortalized HKc/HPV16 to malignant conversion are highly reproducible and at each step the cells progressively acquire phenotypic and biochemical characteristics similar to those found in cell lines established from human tumors.10

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    H. zur Hausen, Papillomaviruses in human cancers, Mol Carcinogenesis 1: 147 (1988).CrossRefGoogle Scholar
  2. 2.
    H. zur Hausen, Papillomaviruses in anogenital cancer as a model to understand the role of viruses in human cancers, Cancer Res 49: 4677 (1989).PubMedGoogle Scholar
  3. 3.
    K.V. Shah, and P.M. Howley, Papillomaviruses, in: “Virology”, B.N. Fields, D.M. Knipe et al., eds. Raven Press, New York (1990).Google Scholar
  4. 4.
    L. Pirisi, S. Yasumoto, M. Feller, J. Doniger, and J.A. DiPaolo, Transformation of human fibroblasts and keratinocytes with human papillomavirus type 16 DNA, J Virol 61: 1061 (1987).PubMedGoogle Scholar
  5. 5.
    L. Pirisi, K.E. Creek, J. Doniger, and J.A. DiPaolo, Continuous cell lines with altered growth and differentiation properties originate after transfection of human keratinocytes with human papillomavirus type 16 DNA, Carcinogenesis 9: 1573 (1988).PubMedCrossRefGoogle Scholar
  6. 6.
    C.D. Woodworth, J. Doniger, and J.A. DiPaolo, Immortalization of human foreskin keratinocytes by various human papillomavirus DNAs corresponds to their association with cervical carcinoma, J Virol 63: 159 (1989).PubMedGoogle Scholar
  7. 7.
    M. Durst, R.T. Dzarlieva-Petrusevska, P. Boukamp, N.E. Fusenig, and L. Gissmann, Molecular and cytogenetic analysis of immortalized human primary keratinocytes obtained after transfection with human papillomavirus type 16 DNA, Oncogene 1: 251 (1987).PubMedGoogle Scholar
  8. 8.
    P. Kaur, and J.K. McDougall, Characterization of primary human keratinocytes transformed by human papillomavirus type 18, J Virol 62: 1917 (1988).PubMedGoogle Scholar
  9. 9.
    C.D. Woodworth, P.E. Bowden, J. Doniger, L. Pirisi, W. Barnes, W.D. Lancaster, and J.A. DiPaolo, Characterization of normal human exocervical epithelial cells immortalized in vitro by papillomavirus types 16 and 18 DNA, Cancer Res 48: 4620 (1988).PubMedGoogle Scholar
  10. 10.
    L.L. Zyzak, L.M. MacDonald, A. Batova, R. Forand, K.E. Creek, and L. Pirisi, Increased levels and constitutive tyrosine phosphorylation of the epidermal growth factor receptor contribute to autonomous growth of human papillomavirus type 16 immortalized human keratinocytes, Cell Growth & Differ 5: 537 (1994).Google Scholar
  11. 11.
    J.A. DiPaolo, C.D. Woodworth, N.C. Popescu, D.L. Koval, J.V. Lopez, and J. Doniger, HSV-2-induced tumorigenicity in HPV16-immortalized human genital keratinocytes, Virology 177: 777 (1989).CrossRefGoogle Scholar
  12. 12.
    J.A. DiPaolo, C.D. Woodworth, N. Popescu, and J. Doniger, Induction of human cervical squamous cell carcinoma by sequential transfection with human papillomavirus type 16 DNA and viral Harvey ras, Oncogene 4: 394 (1989).Google Scholar
  13. 13.
    L. Pirisi, A. Batova, G.R. Jenkins, J.R. Hodam, and K.E. Creek, Increased sensitivity of human keratinocytes immortalized by human papillomavirus type 16 DNA to growth control by retinoids, Cancer Res 52: 187 (1992)PubMedGoogle Scholar
  14. 14.
    K.E. Creek, G.R. Jenkins, M.A. Khan, A. Batova, J.R. Hodam, W.H. Tolleson, and L. Pirisi, Retinoic acid suppresses human papillomavirus type 16 (HPV 16)-mediated transformation of human keratinocytes and inhibits the expression of the HPV16 oncogenes, in: “Diet and Cancer: Markers, Prevention, and Treatment,” M.M. Jacobs, ed. Plenum Press, New York (1994).Google Scholar
  15. 15.
    M.A. Khan, G.R. Jenkins, W.H. Tolleson, K.E. Creek, and L. Pirisi, Retinoic acid inhibition of human papillomavirus type 16-mediated transformation of human keratinocytes, Cancer Res 53: 905 (1993).PubMedGoogle Scholar
  16. 16.
    A. Bernstein, and B. Harris, The relationship of dietary and serum vitamin A to the occurrence or cervical intraepithelial neoplasia in sexually active women, Am J Obstet Gynecol 148: 309 (1984).PubMedGoogle Scholar
  17. 17.
    T. Hirayama, Diet and cancer, Nutr Cancer 1: 67 (1979).CrossRefGoogle Scholar
  18. 18.
    J.R. Marshall, S. Graham, T. Byers, M. Swanson, and J. Brasure, Diet and smoking in the epidemiology of cancer of the cervix, JNatl Cancer Inst 70: 847 (1983).Google Scholar
  19. 19.
    S.L. Romney, P.R. Palan, C. Duttagupta, S. Wassertheil-Smoller, J. Wylie, G. Miller, N.S. Slagle, and D. Lucido, Retinoids and the prevention of cervical dysplasias, Am J Obstet Gynecol 141: 890 (1981).PubMedGoogle Scholar
  20. 20.
    R. Peto, R. Doll, J.D. Buckley, and M.B Sporn, Can dietary beta-carotene materially reduce human cancer rates? Nature 290: 201 (1981).PubMedCrossRefGoogle Scholar
  21. 21.
    J.S. Bertram, L.N. Kolonel, and F.L. Meyskens, Rationale and strategies for chemoprevention of cancers in humans, Cancer Res 47: 3012 (1987).PubMedGoogle Scholar
  22. 22.
    S.M. Lippman, J.F. Kessler, and F.L. Meyskens, Retinoids as preventive and therapeutic anticancer agents (part I), Cancer Treat Rep 71: 391 (1987).PubMedGoogle Scholar
  23. 23.
    S.M. Lippman, S.E. Benner, and W.K. Hong, Chemoprevention: Strategies for the control of cancer, Cancer 72: 984 (1993)PubMedCrossRefGoogle Scholar
  24. 24.
    W.K. Hong, and L.M. Itri, Retinoids and human cancer, in: “The Retinoids: Biology, Chemistry, and Medicine,” M.B. Sporn, A.B. Roberts and D.S. Goodman, eds., p. 597, Raven Press, New York (1994).Google Scholar
  25. 25.
    S.M. Lippman, S.E. Brenner, and W.K. Hong, Cancer chemoprevention, JClin Oncol 12: 851 (1994).Google Scholar
  26. 26.
    V. Graham, E A Surwit, S. Weiner, and F.L. Meyskens, Phase II trial of ß-all-trans-retinoic acid for cervical intraepithelial neoplasia delivered via a collagen sponge and cervical cap, West JMed 145: 192 (1986).Google Scholar
  27. 27.
    F.L. Meyskens, V. Graham, M. Chvapil, R.T. Dorr, D.S. Alberts, and E.A. Surwit, A phase I trial of ß-all-trans-retinoic acid delivered via a collagen sponge and a cervical cap for mild or moderate intraepithelial cervical neoplasia, JNatl Cancer Inst 71:921 (1983).Google Scholar
  28. 28.
    F.L. Meyskens, and E.S. Surwit, Clinical experience with topical tretinoin in the treatment of cervical dysplasia, JAm Acad Dermatol 15: 826 (1986).CrossRefGoogle Scholar
  29. 29.
    Y.M. Peng, D.S. Alberts, V. Graham, E.A. Surwit, S. Weiner, and F.L. Meyskens, Cervical tissue uptake of all-trans-retinoic acid delivered via a collagen sponge-cervical cap delivery device in patients with cervical dysplasia, Invest New Drugs 4: 245 (1986).PubMedCrossRefGoogle Scholar
  30. 30.
    E.A. Surwit, V. Graham, W. Droegemueller, D. Alberts, M. Chvapil, R.T. Dorr, J.R. Davis, and F.L. Meyskens, Evaluation of topically applied trans-retinoic acid in the treatment of cervical intraepithelial lesions, Am J Obstet Gynecol 143: 821 (1982).PubMedGoogle Scholar
  31. 31.
    S.A. Weiner, E.A. Surwit, V.E. Graham, and F.L. Meyskens, A phase I trial of topically applied trans-retinoic acid in cervical dysplasia-clinical efficacy, Invest New Drugs 4: 241 (1986).PubMedCrossRefGoogle Scholar
  32. 32.
    F.L. Meyskens, E. Surwit, T.E. Moon, J.M. Childers, J.R. Davis, R.T. Dorr, C.S. Johnson, and D.S. Alberts, Enhancement of regression of cervical intraepithelial neoplasia (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial, JNatl Cancer Inst 86: 539 (1994).CrossRefGoogle Scholar
  33. 33.
    M.B. Sporn and A.B. Roberts, Cervical dysplasia regression induced by all-trans-retinoic acid, JNatl Cancer Inst 86: 476 (1994).CrossRefGoogle Scholar
  34. 34.
    S.M. Lippman, J.J. Kavanagh, M. Paredes-Espinoza, F. Delgadillo-Madrueno, P. Paredes-Casillas, W.K. Hong, E. Holdener, and I.H. Krakoff, 13-cis-Retinoic acid plus interferon alpha-2a: Highly active systemic therapy for squamous cell carcinoma of the cervix, JNatl Cancer Inst 84: 241 (1992).CrossRefGoogle Scholar
  35. 35.
    S.M. Lippman, J.J. Kavanagh, M. Paredes-Espinoza, F. Delgadillo-Madrueno, P. Paredes-Casillas, W.K. Hong, G. Massimini, E. E. Holdener, and I.H. Krakoff, 13-cis-Retinoic acid plus interferon alpha-2a in locally advanced squamous cell carcinoma of the cervix, JNatl Cancer Inst 85: 499 (1993).CrossRefGoogle Scholar
  36. 36.
    G.D. Shipley, M.R. Pittelkow, J.J. Wille, R.E. Scott, and H.L. Moses, Reversible inhibition of normal human prokeratinocyte proliferation by type ß transforming growth factor-growth inhibitor in serum-free medium, Cancer Res 46: 2068 (1986).PubMedGoogle Scholar
  37. 37.
    R.J. Coffey, C.C. Bascom, N.J. Sipes, R. Graves-Deal, B.E. Weissman, and H.L. Moses, Selective inhibition of growth-related gene expression in murine keratinocytes by transforming growth factor ß, Mol Cell Bio18: 3088 (1988).Google Scholar
  38. 38.
    R.J. Coffey, N.J. Sipes, C.C. Bascom, R. Graves-Deal, C.Y. Pennington, B.E. Weissman and H.L. Moses, Growth modulation of mouse keratinocytes by transforming growth factors, Cancer Res 48: 1596 (1988).PubMedGoogle Scholar
  39. 39.
    M. Reiss, and A.C. Sartorelli, Regulation of growth and differentiation of human keratinocytes by type ß transforming growth factor and epidermal growth factor, Cancer Res 47: 6705 (1987).PubMedGoogle Scholar
  40. 40.
    K. Matsumoto, K. Hashimoto, M. Hashiro, H. Yoshimasa, and K. Yoshikawa, Modulation of growth and differentiation in normal human keratinocytes by transforming growth factor-ß, J Cell Physiol 145: 95 (1990).PubMedCrossRefGoogle Scholar
  41. 41.
    A.B. Glick, K.C. Flanders, D. Danielpour, S.H. Yuspa, and M.B. Sporn, Retinoic acid induces transforming growth factor-ß2 in cultured keratinocytes and mouse epidermis, Cell Regulation 1: 87 (1989).PubMedGoogle Scholar
  42. 42.
    A. Batova, D. Danielpour, L. Pirisi, and K.E. Creek, Retinoic acid induces secretion of latent transforming growth factor ß 1 and ß2 in normal and human papillomavirus type 16-immortalized human keratinocytes, Cell Growth & Differ 3: 763 (1992).Google Scholar
  43. 43.
    C.D. Woodworth, V. Notario, and J.A. DiPaolo, Transforming growth factors beta 1 and 2 transcriptionally regulate human papillomavirus (HPV) type 16 early gene expression in HPV-immortalized human genital epithelial cells, J Tirol 64: 4767 (1990).Google Scholar
  44. 44.
    D. Bartsch, B. Boye, C. Baust, H. zur Hausen, and E. Schwarz, Retinoic acid-mediated repression of human papillomavirus 18 transcription and different ligand regulation of the retinoic acid receptor ß gene in non-tumorigenic and tumorigenic HeLa hybrids, EMBO J 11: 2283 (1992).PubMedGoogle Scholar
  45. 45.
    L. Madisen, N.R. Webb, T.M. Rose, H. Marquardt, T. Ikeda, D. Twardzik, S Seyedin, and A.F. Purchio, Transforming growth factor-ß2: cDNA cloning and sequence analysis, DNA 7: 1 (1988).PubMedCrossRefGoogle Scholar
  46. 46.
    L.M. Wakefield, D.M. Smith, T. Masui, C.C. Harris, and M.B. Sporn, Distribution and modulation of the cellular receptor for transforming growth factor-beta, J Cell Biol 105: 965 (1987).PubMedCrossRefGoogle Scholar
  47. 47.
    R. Pircher, D.A. Lawrence, and P. Jullien, Latent beta-transforming growth factor in nontransformed and Kirsten sarcoma virus-transformed normal rat kidney cells, clone 49F, Cancer Res 44: 5538 (1984).PubMedGoogle Scholar
  48. 48.
    P.A. Dennis, and D.B. Rifkin, Cellular activation of latent transforming growth factor ß requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor, Proc Natl Acad Sci USA 88: 580 (1991).PubMedCrossRefGoogle Scholar
  49. 49.
    C.A. Frolik, and J.E. DeLarco, Radioreceptor assay for transforming growth factors, Methods Enzymol 146: 95 (1987).PubMedCrossRefGoogle Scholar
  50. 50.
    L.M. Wakefield, An assay for type-ß transforming growth factor receptor, Methods Enzymol 146: 167–173 (1987).PubMedCrossRefGoogle Scholar
  51. 51.
    S. Yasumoto, J. Doniger, and J.A. DiPaolo, Differential early viral gene expression in two stages of human papillomavirus type 16 DNA-induced malignant transformation, Mol Cell Biol 7: 2165 (1987).PubMedGoogle Scholar
  52. 52.
    E. Ohmura, M. Okada, N. Onoda, Y. Kamiya, H. Murakami, T. Tsushima, and K. Shizume, Insulin-like growth factor I and transforming growth factor a as autocrine growth factors in human pancreatic cancer cell growth, Cancer Res 50: 103 (1990).PubMedGoogle Scholar
  53. 53.
    M.A. Anzano, D. Rieman, W. Prichett, D.F. Bowen-Pope, and R. Greig, Growth factor production by human colon carcinoma cell lines, Cancer Res 49: 2898 (1989).PubMedGoogle Scholar
  54. 54.
    D.R. Hofer, E.R. Sherwood, W.D. Bromberg, J. Mendelsohn, C. Lee, and J.M. Kozlowski, Autonomous growth of androgen-independent human prostatic carcinoma cells: Role of transforming growth factor a, Cancer Res 51: 2780 (1991).PubMedGoogle Scholar
  55. 55.
    M.-E. Forgue-Lafitte, A.-M. Coudray, B. Breant, and J. Mester, Proliferation of the human colon carcinoma cell line HT29: Autocrine growth and deregulated expression of the c-myc oncogene, Cancer Res 49: 6566 (1989).PubMedGoogle Scholar
  56. 56.
    R. Kurokawa, S. Kyakumoto, and M. Ota, Autocrine growth factor in defined serum-free medium of human salivary gland adenocarcinoma cell line HSG, Cancer Res 49: 5136 (1989).PubMedGoogle Scholar
  57. 57.
    M.B. Sporn, and A.B. Roberts, Autocrine growth factors and cancer, Nature 313: 745 (1985).PubMedCrossRefGoogle Scholar
  58. 58.
    M. Reiss, E.B. Stash, V.F. Vellucci, and Z.-L. Zhou, Activation of the autocrine transforming growth factor a pathway in human squamous carcinoma cells, Cancer Res 51: 6254 (1991).PubMedGoogle Scholar
  59. 59.
    V.M. Macaulay, M.J. Everard, J.D. Teale, P.A. Trott, J.J. Van Wyk, I.E. Smith, and J.L. Millar, Autocrine function for insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumor cells, Cancer Res 50: 2511 (1990).PubMedGoogle Scholar
  60. 60.
    O.M. El-Badiy, C. Minniti, E.C. Kohn, P.J. Houghton, W.H. Daughaday, and L.J. Helman, Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors, Cell Growth Differ 1: 325 (1990).Google Scholar
  61. 61.
    R. Derynck, D.V. Goeddel, A. Ullrich, J.U. Guttennan, R.D. Williams, T.S. Bringman, and W.H. Berger, Synthesis of messenger RNAs for transforming growth factors a and ß and the epidermal growth factor receptor by human tumors, Cancer Res 47: 707 (1987).PubMedGoogle Scholar
  62. 62.
    J.H. Mydlo, J. Michaeli, C. Cordon-Cardo, A.S. Goldenberg, W.D.W. Heston, and W.R. Fair, Expression of transforming growth factor a and epidermal growth factor receptor messenger RNA in neoplastic and nonneoplastic human kidney tissue, Cancer Res 49: 3407 (1989).PubMedGoogle Scholar
  63. 63.
    A. Goppinger, F.M. Wittmaack, H.O. Wintzer, H. Ikenberg, and T. Bauknecht, Localization of human epidermal growth factor receptor in cervical intraepithelial neoplasias, J Cancer Res Clin Oncol 115: 259 (1989).PubMedCrossRefGoogle Scholar
  64. 64.
    T. Bauknecht, M. Kohler, I. Janz, and A. Pfleiderer, The occurrence of epidermal growth factor receptors and the characterization of EGF-like factors in human ovarian, endometrial, cervical and breast cancer, J Cancer Res Clin Oncol 115: 193 (1989).PubMedCrossRefGoogle Scholar
  65. 65.
    W. Gullick, J.J. Marsden, N. Whittle, B. Ward, L. Bobrow, and M.D. Waterfield, Expression of epidermal growth factor receptors on human cervical, ovarian, and vulval carcinomas, Cancer Res 46: 285 (1986)PubMedGoogle Scholar
  66. 66.
    D. Danielpour, K.-Y. Kim, L.L. Dart, S. Watanabe, A.B. Roberts, and M.B. Sporn, Sandwich enzyme-linked immunosorbent assays (SELISAs) quantitate and distinguish two forms of transforming growth factor-beta (TGF-ß1 and TGF-ß2) in complex biological fluids, Growth Factors 2: 61 (1989).PubMedCrossRefGoogle Scholar
  67. 67.
    A.B. Glick, D. Danielpour, D. Morgan, M.B. Sporn, and S.H. Yuspa, Induction and autocrine receptor binding of transforming growth factor-ß2 during terminal differentiation of primary mouse keratinocytes, Mol Endocrin 4: 46 (1990).CrossRefGoogle Scholar
  68. 68.
    J.A. Pietenpol, R.W. Stein, E. Moran, P. Yaciuk, R. Schlegel, R.M. Lyons, M.R. Pittelkow, K. Munger, P.M. Howley, and H.L. Moses, TGF-ß1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains. Cell 61: 777 (1990).PubMedCrossRefGoogle Scholar
  69. 69.
    T. Crook, J.P. Morgenstern, L. Crawford, and L. Banks, Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras, EMBO J 8: 513 (1989).PubMedGoogle Scholar
  70. 70.
    C. Agarwal, E.A. Rorke, J.C. Irwin, and R.L. Eckert, Immortalization by human papillomavirus type 16 alters retinoid regulation of human ectocervical epithelial cell differentiation, Cancer Res 51: 3982 (1991).PubMedGoogle Scholar
  71. 71.
    C.D. Hebert, and L.S. Birnbaum, Lack of correlation between sensitivity to growth inhibition and receptor number for transforming growth factor ß in human squamous carcinoma cell lines, Cancer Res 49: 3196 (1989).PubMedGoogle Scholar
  72. 72.
    L. Braun, M. Durst, R. Mikumo, and P. Gruppuso, Differential response of nontumorigenic and tumorigenic human papillomavirus type 16-positive epithelial cells to transforming growth factor ßl, Cancer Res 50: 7324 (1990).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • Kim E. Creek
    • 1
  • Gemma Geslani
    • 2
  • Ayse Batova
    • 2
  • Lucia Pirisi
    • 3
  1. 1.Children’s Cancer Research Laboratory Department of Pediatrics, and Department of PathologyUniversity of South Carolina School of MedicineColumbiaUSA
  2. 2.Department of Chemistry and BiochemistryUniversity of South CarolinaColumbiaUSA
  3. 3.Department of PathologyUniversity of South Carolina School of MedicineColumbiaUSA

Personalised recommendations